Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**Fonsecaea** associated cerebral phaeohyphomycosis in a post-COVID-19 patient: A first case report

Simin Laiq a, b, Mubarak Al Yaqoobi b, Maimuna Al Saadi a, Semee Rizvi b, Zahra Al Hajri a, Saleh Al Azri b, Khalsa Al Ramadhani c, Qasim Al Hinai d

a Department of Histopathology, Directorate General of Khoula Hospital, Muscat, Oman
b Department of Microbiology, Directorate General of Khoula Hospital, Muscat, Oman
c Department of Radiology, Directorate General of Khoula Hospital, Muscat, Oman
d Department of Neurosurgery, Directorate General of Khoula Hospital, Muscat, Oman

**ARTICLE INFO**

**Keywords:**
Cerebral phaeohyphomycosis
Brain abscess
Dematiaceous fungi
Pigmented fungi
Chromoblastomycosis
Fonsecaea
COVID-19
SARS-CoV-2

**ABSTRACT**

Phaeohyphomycosis, previously known as chromoblastomycosis, is a chronic mycosis, usually affecting the skin. It is caused by dematiaceous fungi, which are a group of fungi that produce melanin in their cell walls. Cerebral phaeohyphomycosis occurs as part of invasive presentation of the fungi, which usually affects immunocompromised patients, but may affect immunocompetent individuals as well. Cerebral infection in phaeohyphomycosis is associated with a poor prognosis regardless of the immune status of the patient. COVID-19 SARS-CoV-2 infection and/or medications used for its treatment may compromise the immune system, including in the post-COVID-19 period, resulting in invasive fungal infections, which have frequently been reported recently during the COVID-19 pandemic. We report a case of *Fonsecaea* associated cerebral phaeohyphomycosis in a recently diagnosed diabetic Omani lady, who presented to our hospital 6 weeks after recovery and discharge from hospitalization for moderate COVID-19 pneumonia.

**Introduction**

Cerebral fungal infections are relatively uncommon, and mostly affect immunocompromised patients. Only a few fungi are capable of causing disease in immunocompetent individuals (Davis, 1999). Most fungi live in the soil or on vegetation and infect humans only occasionally, by inhalation or through puncture wounds. Fungal infections usually reach the brain either by hematogenous route or by direct extension of infections from sinuses, ear canal or bone, or by direct inoculation secondary to cranial trauma or neurosurgical interventions (Chakrabarti, 2007).

Phaeohyphomycosis, previously known as chromoblastomycosis, is an infection caused by dematiaceous fungi, which are a group of fungi that produce melanin in their cell walls (Larone, 2011). Phaeohyphomycosis usually affect the skin, causing chronic mycosis. Cerebral phaeohyphomycosis occurs as a part of invasive presentation of the fungi, which usually affects immunocompromised patients, but may affect immunocompetent individual as well (Revankar et al., 2004). Cerebral infection in phaeohyphomycosis is associated with a poor prognosis regardless of the immune status of the patient (Revankar et al., 2004).

COVID-19 disease, caused by SARS-CoV-2 coronavirus, was declared a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020 by the World Health Organization (World Health Organization, 2005; World Health Organization, 2020). Since then the COVID-19 pandemic is still continuously evolving, and its associated pathophysiology and complications are continuously being discovered. Invasive fungal infections particularly Mucormycosis and Aspergillosis are not uncommon, generally or as a complication of COVID-19 infection and have been reported frequently during the COVID-19 pandemic (Soman and Sunavala, 2021; Manchanda et al., 2021). Invasive fungal infections caused by other fungi such as *Fonsecaea* are uncommon or rare. We report a case of *Fonsecaea* associated cerebral phaeohyphomycosis in a recently diagnosed diabetic Omani lady, who presented to our hospital 6 weeks after recovery and discharge from hospitalization for moderate COVID-19 pneumonia.
Clinical report

A 73-year-old Omani lady presented with 1-week history of occipital headache, unsteady gait and visual disturbance with blurred vision, and a 2-day history of confusion. She was known to have hypertension and was recently diagnosed with non-insulin dependent type-2 diabetes (6 months prior to presenting at our hospital). She was also diagnosed to have COVID-19 infection, 9 weeks prior to presentation at our hospital. She had no other known immunodeficiencies and testing for HIV-1 and HIV-2 antigens and antibodies was negative.

During her COVID-19 infection, she developed COVID-19 pneumonia, which was mild initially, and treated with oral antibiotics and steroids (dexamethasone 6 mg/OD) at home, but later the pneumonia became severe enough to require 4-day hospitalization and oxygen support via high flow nasal cannula. In-hospital, she received steroids (intravenous dexamethasone (6 mg/OD)) and antibiotic treatment (cefuroxime followed by ceftriaxone) for suspected superadded bacterial infection. Prior to admission for COVID-19 she was on oral hypoglycemics for control of her diabetes, but during her hospital stay, her blood glucose became uncontrolled, for which she required insulin injections. She was discharged from hospital on day-18 of COVID-19 infection, with a prescription for insulin for diabetes.

She then presented to our hospital 6 weeks after discharge for her COVID-19 pneumonia. On examination, she was confused, not oriented and Glasgow coma scale was 14/15 (E4M6V4). Motor examination was unremarkable and gait examination was difficult to assess due to her confusion. COVID-19 testing by PCR, on day of admission was negative. Her glycated hemoglobin (HbA1c) was 9.95% (reference range 4.4–6.4%). Brain imaging showed a rim enhancing lesion in the left parieto-occipital region with surrounding vasogenic edema (Fig. 1). The differential diagnoses of brain abscess and tumor were considered. She was given intravenous dexamethasone to reduce brain edema. She later underwent a left-parieto-occipital craniotomy and excision of lesion. The initial microscopic examination showed fungal hyphae on Gram stain. For histopathology examination the lesional tissue was fixed in 10% neutral buffered formalin, embedded in paraffin, serial sectioned at 5 μm, and stained with hematoxylin and eosin (H&E), Periodic acid-Schiff stain (PAS), and Grocott’s methenamine silver stain (GMS) and the pathology revealed a brain abscess with mixed inflammatory cell infiltrate (consisting of neutrophils, lymphocytes, plasma cells and histiocytes), reactive astrocytes, and numerous pigmented brown septate branching fungal hyphae, best seen on H&E. A morphologic diagnosis of brain abscess with pigmented fungal organisms in keeping with cerebral phaeohyphomycosis was made (Fig. 2). Additional lesional tissue was submitted for fungal cultures. For the fungal cultures, the sample was inoculated onto Chocolate agar (Fig. 3 A) and Sabouraud dextrose agar (Fig. 3 B) plates. The plates were incubated at 30 °C and fungal growth was observed 1 week after incubation. The slow-growing colonies were greyish black in color, covered with a fine velvety mycelium, and produced a raised convex protrusion at the centers. Microscopically, smears made from the agar culture plates showed septate, loosely branching fungal hyphae with ‘budding’ growth of conidia.
The fungus was identified as *Fonsecaea species* based on morphology (Fig. 3 C, D). She was started empirically on liposomal amphotericin antifungal agent as well as ceftriaxone. Postoperatively, she did poorly, with declining level of consciousness and development of deranged liver enzymes. A second redo parieto-occipital craniotomy and excision drainage of abscess was done about 2 weeks after initial surgery, which revealed development of a superadded bacterial infection.

She was initially given meropenem. Voriconazole was started in the following days, which was later switched to oral posaconazole suspension, due to side effects. Vancomycin was also added, but despite addition of new antibiotics, she kept deteriorating and developed sepsis.

Vancomycin was also added, but despite addition of new antibiotics, she kept deteriorating and developed sepsis. She unfortunately had a cardiac arrest and passed away 6 weeks after admission. (Fig. 4 shows the complete timeline representing the clinical course of patients’ COVID-19, COVID-19 pneumonia and *Fonsecaea* associated cerebral phaeohyphomycosis).

**Discussion**

Cerebral phaeohyphomycosis is a rare brain fungal infection that can affect immunocompetent and immunocompromised individuals (Revankar et al., 2004). It is caused by a wide variety of pigmented dematiaceous fungi, most common being *Cladophialophora bantiana*, *Rhinocladiella mackenziei* and *Exophiala dermatitidis* (Larone, 2011; Revankar et al., 2004; Garzoni et al., 2008; Brandt and Warnock, 2003).

Cerebral phaeohyphomycosis has variable central nervous system (CNS) manifestations, with brain abscess being the most classic clinical presentation (Revankar et al., 2004). Other manifestations include meningitis, encephalitis, myelitis and arachnoiditis (Revankar et al., 2004).

Fungi genus *Fonsecaea* is morphologically defined by the presence of melanized pigmented (dark/brown) septate, loosely branching hyphae, and pale brown or olivaceous conidia produced in short chains at the apex of the conidiophores (Larone, 2011). *Fonsecaea* is present worldwide, but it is more commonly prevalent in tropical and sub-tropical regions, and it is a saprobe, living on dead organic matter in the soil and rotting plant materials (Larone, 2011). Four species of *Fonsecaea* namely, *F. pedrosoi*, *F. monophora*, *F. rubica* and *F. pugnacius*, are currently recognized to cause disease in humans (Najafzadeh et al., 2009; Xi et al., 2009; de Azevedo et al., 2015; Costa et al., 2016; Bagla et al., 2016).

Our patient was relatively immunocompetent prior to getting COVID-19 infection. Her COVID-19 pneumonia was treated with steroids, and her diabetic glucose control worsened during the course of her COVID-19 infection. 6 weeks after her hospital discharge for COVID-19 pneumonia, she presented to our hospital with a brain abscess, which on histopathology showed a slow-growing fungus *Fonsecaea* associated cerebral phaeohyphomycosis. As COVID-19 pandemic is still underway, currently only fungal Mucormycosis and Aspergillosis infections have so far been reported affecting patients infected and recovering from COVID-19 (Soman and Sunavala, 2021; Manchanda et al., 2021). These patients have become immunocompromised due to different factors including the disease itself; exacerbation of existing chronic conditions such as diabetes mellitus during COVID-19 infection; and by using steroids and monoclonal antibody for treatment of COVID-19 (Pranata et al., 2021). COVID-19 infection is associated with development and
exacerbation of diabetes mellitus as part of COVID-19 disease and post-COVID-19 syndrome (Pranata et al., 2021). In our case, we hypothesize that the patients’ treatment with steroids, and her exacerbation of diabetes during COVID-19 infection, lead her to be immunocompromised and more susceptible to fungal infections, and ours is the first reported case of a different fungal infection affecting a post-COVID-19 patient.

**Conclusion**

_Fonsecaea_ associated cerebral phaeohyphomycosis is a serious fungal infection associated with high mortality. This is the first report worldwide, to our knowledge, that describes a case of _Fonsecaea_ associated cerebral phaeohyphomycosis in a patient with recent COVID-19 infection. With the COVID-19 pandemic still continuously evolving, we should keep a low clinical threshold for invasive mould infections.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References

Bagla, P., Loeffelholz, M., Blanton, L.S., 2016. Cerebral phaeohyphomycosis by Fonsecaea monophora: Report in a patient with AIDS and a ring enhancing lesion. Med. Mycol. Case Rep. 12, 4–7. https://doi.org/10.1016/j.mmcr.2016.06.002. Published 2016 Jun 20.

Brandt, M.E., Warnock, D.W., 2003. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J. Chemother. 15 (Suppl 2), 36–47. https://doi.org/10.1179/joc.2003.15.

Chakrabarti, A., 2007. Epidemiology of central nervous system mycoses. Neurol. India 55 (3), 191–197. https://doi.org/10.4103/0028-3886.35679.

Costa, F.F., de Hoog, S., Raittz, R.T., et al. Draft Genome Sequence of Fonsecaea nubica Strain CBS 269.64, Causative Agent of Human Chromoblastomycosis. Genome Announc. 2016;4(4):e00735-16. Published 2016 Aug 4. doi:10.1128/genomeA.00735-16.

Davis, L.E., 1999. Fungal infections of the central nervous system. Neurol. Clin. 17 (4), 761–781. https://doi.org/10.1016/s0733-8619(05)70165-1.

de Azevedo, C.M.P.S., Gomes, R.B., Vicente, V.A., Santos, D.W.C.L., Marques, S.G., do Nascimento, M.M.F., Andrade, C.E.W., Silva, R.R., Queiroz-Telles, F., de Hoog, G.S., Warnock, D.W., 2015. Fonsecaea pugnacius, a novel agent of disseminated chromoblastomycosis. J. Clin. Microbiol. 53 (8), 2674–2685. https://doi.org/10.1128/JCM.00657-15.

Garzoni, C., Markham, L., Bijlenga, P., Garbino, J., 2008. Cladophialophora bantiana: a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options. Med. Mycol. 46 (5), 481–486. https://doi.org/10.1080/13693780801914906.

Larone, D.H., 2011. Medically Important Fungi: A Guide to Identification, American Society for Microbiology (ASM), Washington, DC, USA, 5th edition.

Manchanda, S., Semalti, K., Bhalla, A.S., Thakar, A., Sikka, K., Verma, H., 2021. Revisiting rhino-orbito-cerebral acute invasive fungal sinusitis in the era of COVID-19: pictorial review [published online ahead of print, 2021 Aug 31]. Emerg Radiol., 1-10. doi:10.1007/s10140-021-01980-9.

Najafzadeh, M.J., Goetian, C., Badali, H., Van Den Ende, A.H., Xi, L., De Hoog, G.S., 2009. Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Med. Mycol. 47 (1), 17–25. https://doi.org/10.1080/13693780802529793.

Pranata, R., Henrina, J., Raffaello, W.M., Lawrensia, S., Huang, I., 2021. Diabetes and COVID-19: The past, the present, and the future. Metabolism. 121, 154814. https://doi.org/10.1016/j.metabol.2021.154814.

Revankar, S.G., Sutton, D.A., Rinaldi, M.G., 2004. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin. Infect. Dis. 38 (2), 206–216. https://doi.org/10.1086/cid.2004.38.issue-210.1086/380635.

Soman, R., Sunavala, A., 2021. Post COVID-19 Mucormycosis - from the Frying Pan into the Fire. J. Assoc. Physicians India 69 (1), 13–14.

World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 30 January 2020 Statement. Geneva, Switzerland. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.

Xi, L., Sun, J., Lu, C., Liu, H., Xie, Z., Fukushima, K., Takizawa, K., Najafzadeh, M.J., Hoog, G.S.D., 2009. Molecular diversity of Fonsecaea (Chaetothyriales) causing chromoblastomycosis in southern China. Med. Mycol. 47 (1), 27–33. https://doi.org/10.1080/13693780802468209.